These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 38530357)

  • 1. Pharmacological suppression of the OTUD4/CD73 proteolytic axis revives antitumor immunity against immune-suppressive breast cancers.
    Zhu Y; Banerjee A; Xie P; Ivanov AA; Uddin A; Jiao Q; Chi JJ; Zeng L; Lee JY; Xue Y; Lu X; Cristofanilli M; Gradishar WJ; Henry CJ; Gillespie TW; Bhave MA; Kalinsky K; Fu H; Bahar I; Zhang B; Wan Y
    J Clin Invest; 2024 Mar; 134(10):. PubMed ID: 38530357
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Posttranslational protein modifications as gatekeepers of cancer immunogenicity.
    Marchese E; Demehri S
    J Clin Invest; 2024 May; 134(10):. PubMed ID: 38747288
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeting CD73 and downstream adenosine receptor signaling in triple-negative breast cancer.
    Allard B; Turcotte M; Stagg J
    Expert Opin Ther Targets; 2014 Aug; 18(8):863-81. PubMed ID: 24798880
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CD73 promotes anthracycline resistance and poor prognosis in triple negative breast cancer.
    Loi S; Pommey S; Haibe-Kains B; Beavis PA; Darcy PK; Smyth MJ; Stagg J
    Proc Natl Acad Sci U S A; 2013 Jul; 110(27):11091-6. PubMed ID: 23776241
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CD73: an emerging checkpoint for cancer immunotherapy.
    Chen S; Wainwright DA; Wu JD; Wan Y; Matei DE; Zhang Y; Zhang B
    Immunotherapy; 2019 Aug; 11(11):983-997. PubMed ID: 31223045
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CD73 facilitates EMT progression and promotes lung metastases in triple-negative breast cancer.
    Petruk N; Tuominen S; Åkerfelt M; Mattsson J; Sandholm J; Nees M; Yegutkin GG; Jukkola A; Tuomela J; Selander KS
    Sci Rep; 2021 Mar; 11(1):6035. PubMed ID: 33727591
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Chemotherapy induces enrichment of CD47
    Samanta D; Park Y; Ni X; Li H; Zahnow CA; Gabrielson E; Pan F; Semenza GL
    Proc Natl Acad Sci U S A; 2018 Feb; 115(6):E1239-E1248. PubMed ID: 29367423
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dual Mechanisms of Novel CD73-Targeted Antibody and Antibody-Drug Conjugate in Inhibiting Lung Tumor Growth and Promoting Antitumor Immune-Effector Function.
    Jin R; Liu L; Xing Y; Meng T; Ma L; Pei J; Cong Y; Zhang X; Ren Z; Wang X; Shen J; Yu K
    Mol Cancer Ther; 2020 Nov; 19(11):2340-2352. PubMed ID: 32943546
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Proteolytic regulation of CD73 by TRIM21 orchestrates tumor immunogenicity.
    Fu Z; Chen S; Zhu Y; Zhang D; Xie P; Jiao Q; Chi J; Xu S; Xue Y; Lu X; Song X; Cristofanilli M; Gradishar WJ; Kalinsky K; Yin Y; Zhang B; Wan Y
    Sci Adv; 2023 Jan; 9(1):eadd6626. PubMed ID: 36608132
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CD73-adenosine: a next-generation target in immuno-oncology.
    Allard D; Allard B; Gaudreau PO; Chrobak P; Stagg J
    Immunotherapy; 2016 Feb; 8(2):145-63. PubMed ID: 26808918
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Downregulation of CD73 associates with T cell exhaustion in AML patients.
    Kong Y; Jia B; Zhao C; Claxton DF; Sharma A; Annageldiyev C; Fotos JS; Zeng H; Paulson RF; Prabhu KS; Zheng H
    J Hematol Oncol; 2019 Apr; 12(1):40. PubMed ID: 31014364
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Boost Infiltration and Activity of T Cells via Inhibiting Ecto-5'-nucleotidase (CD73) Immune Checkpoint to Enhance Glioblastoma Immunotherapy.
    Zhang H; Yang L; Han M; Han Y; Jiang Z; Zheng Q; Dong J; Wang T; Li Z
    ACS Nano; 2024 Aug; 18(34):23001-23013. PubMed ID: 39150454
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical significance of CD73 in triple-negative breast cancer: multiplex analysis of a phase III clinical trial.
    Buisseret L; Pommey S; Allard B; Garaud S; Bergeron M; Cousineau I; Ameye L; Bareche Y; Paesmans M; Crown JPA; Di Leo A; Loi S; Piccart-Gebhart M; Willard-Gallo K; Sotiriou C; Stagg J
    Ann Oncol; 2018 Apr; 29(4):1056-1062. PubMed ID: 29145561
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CD73 contributes to anti-inflammatory properties of afferent lymphatic endothelial cells in humans and mice.
    Eichin D; Pessia A; Takeda A; Laakkonen J; Bellmann L; Kankainen M; Imhof BA; Stoitzner P; Tang J; Salmi M; Jalkanen S
    Eur J Immunol; 2021 Jan; 51(1):231-246. PubMed ID: 32970335
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeting CD73 limits tumor progression and enhances anti-tumor activity of anti-PD-1 therapy in intrahepatic cholangiocarcinoma.
    Sun BY; Zhang D; Gan W; Wu JF; Wang ZT; Sun GQ; Zhou J; Fan J; Yi Y; Hu B; Zhang BH; Qiu SJ
    J Cancer Res Clin Oncol; 2024 Jul; 150(7):348. PubMed ID: 39002018
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CD73 blockade enhances the local and abscopal effects of radiotherapy in a murine rectal cancer model.
    Tsukui H; Horie H; Koinuma K; Ohzawa H; Sakuma Y; Hosoya Y; Yamaguchi H; Yoshimura K; Lefor AK; Sata N; Kitayama J
    BMC Cancer; 2020 May; 20(1):411. PubMed ID: 32397971
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Specific blockade CD73 alters the "exhausted" phenotype of T cells in head and neck squamous cell carcinoma.
    Deng WW; Li YC; Ma SR; Mao L; Yu GT; Bu LL; Kulkarni AB; Zhang WF; Sun ZJ
    Int J Cancer; 2018 Sep; 143(6):1494-1504. PubMed ID: 29663369
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CD73 immune checkpoint defines regulatory NK cells within the tumor microenvironment.
    Neo SY; Yang Y; Record J; Ma R; Chen X; Chen Z; Tobin NP; Blake E; Seitz C; Thomas R; Wagner AK; Andersson J; de Boniface J; Bergh J; Murray S; Alici E; Childs R; Johansson M; Westerberg LS; Haglund F; Hartman J; Lundqvist A
    J Clin Invest; 2020 Mar; 130(3):1185-1198. PubMed ID: 31770109
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Generating tumor-selective conditionally active biologic anti-CTLA4 antibodies via protein-associated chemical switches.
    Chang HW; Frey G; Liu H; Xing C; Steinman L; Boyle WJ; Short JM
    Proc Natl Acad Sci U S A; 2021 Mar; 118(9):. PubMed ID: 33627407
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacologic Suppression of B7-H4 Glycosylation Restores Antitumor Immunity in Immune-Cold Breast Cancers.
    Song X; Zhou Z; Li H; Xue Y; Lu X; Bahar I; Kepp O; Hung MC; Kroemer G; Wan Y
    Cancer Discov; 2020 Dec; 10(12):1872-1893. PubMed ID: 32938586
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.